{"id":1011698,"date":"2021-05-09T11:37:14","date_gmt":"2021-05-09T15:37:14","guid":{"rendered":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/leerink-partners-stick-to-their-buy-rating-for-stryker-corporation-by-investing-com-investing-com\/"},"modified":"2021-05-09T11:37:14","modified_gmt":"2021-05-09T15:37:14","slug":"leerink-partners-stick-to-their-buy-rating-for-stryker-corporation-by-investing-com-investing-com","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/leerink-partners-stick-to-their-buy-rating-for-stryker-corporation-by-investing-com-investing-com\/","title":{"rendered":"Leerink Partners Stick to Their Buy Rating for Stryker Corporation By Investing.com &#8211; Investing.com"},"content":{"rendered":"<p><p>Leerink Partners analyst Richard Newitter maintained a Buy rating on  Stryker  Corporation (NYSE:) on Wednesday, setting a price target of $290, which is approximately 10.42% above the present share price of $262.63.<\/p>\n<p>Newitter expects Stryker Corporation to post earnings per share (EPS) of $0.80 for the second quarter of 2021.<\/p>\n<p>The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $277.The analysts price targets range from a high of $303 to a low of $248.<\/p>\n<p>In its latest earnings report, released on 03\/31\/2021, the company reported a quarterly revenue of $3.95 billion and a net profit of $465 million. The company's market cap is $98.83 billion.<\/p>\n<p>According to TipRanks.com, Leerink Partners analyst Richard Newitter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.1% and a 70.43% success rate.<\/p>\n<p>Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.<\/p>\n<p>Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy\/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Visit link: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.investing.com\/news\/leerink-partners-stick-to-their-buy-rating-for-stryker-corporation-2492567\" title=\"Leerink Partners Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com\">Leerink Partners Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Leerink Partners analyst Richard Newitter maintained a Buy rating on Stryker Corporation (NYSE:) on Wednesday, setting a price target of $290, which is approximately 10.42% above the present share price of $262.63. Newitter expects Stryker Corporation to post earnings per share (EPS) of $0.80 for the second quarter of 2021. The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $277.The analysts price targets range from a high of $303 to a low of $248 <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/leerink-partners-stick-to-their-buy-rating-for-stryker-corporation-by-investing-com-investing-com\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187755],"tags":[],"class_list":["post-1011698","post","type-post","status-publish","format-standard","hentry","category-neurotechnology"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1011698"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=1011698"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1011698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=1011698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=1011698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=1011698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}